about
Safety profile of the respiratory fluoroquinolone moxifloxacin: comparison with other fluoroquinolones and other antibacterial classesCharacterization of Abcc4 gene amplification in stepwise-selected mouse J774 macrophages resistant to the topoisomerase II inhibitor ciprofloxacinAnalysis of the membrane proteome of ciprofloxacin-resistant macrophages by stable isotope labeling with amino acids in cell culture (SILAC)Antibiotic activity against small-colony variants of Staphylococcus aureus: review of in vitro, animal and clinical data.Predicting the three-dimensional structure of human P-glycoprotein in absence of ATP by computational techniques embodying crosslinking data: insight into the mechanism of ligand migration and binding sites.Activity of three {beta}-lactams (ertapenem, meropenem and ampicillin) against intraphagocytic Listeria monocytogenes and Staphylococcus aureus.Molecular models of human P-glycoprotein in two different catalytic statesIsolation and 2-D-DIGE proteomic analysis of intracellular and extracellular forms of Listeria monocytogenes.Penicillin-binding proteins (PBP) and Lmo0441 (a PBP-like protein) play a role in Beta-lactam sensitivity of Listeria monocytogenes.Accumulation and oriented transport of ampicillin in Caco-2 cells from its pivaloyloxymethylester prodrug, pivampicillin.Mixed-lipid storage disorder induced in macrophages and fibroblasts by oritavancin (LY333328), a new glycopeptide antibiotic with exceptional cellular accumulationIntra- and extracellular activities of dicloxacillin against Staphylococcus aureus in vivo and in vitro.Appropriateness of use of medicines in elderly inpatients: qualitative study.Comparative intracellular (THP-1 macrophage) and extracellular activities of beta-lactams, azithromycin, gentamicin, and fluoroquinolones against Listeria monocytogenes at clinically relevant concentrationsComparative stability studies of antipseudomonal beta-lactams for potential administration through portable elastomeric pumps (home therapy for cystic fibrosis patients) and motor-operated syringes (intensive care units)Moxifloxacin safety: an analysis of 14 years of clinical data.Tackling antibiotic resistance.Cellular pharmacodynamics of the novel biaryloxazolidinone radezolid: studies with infected phagocytic and nonphagocytic cells, using Staphylococcus aureus, Staphylococcus epidermidis, Listeria monocytogenes, and Legionella pneumophilaCellular accumulation and activity of quinolones in ciprofloxacin-resistant J774 macrophagesInfluence of P-glycoprotein inhibitors on accumulation of macrolides in J774 murine macrophages.Nonclinical and pharmacokinetic assessments to evaluate the potential of tedizolid and linezolid to affect mitochondrial functionActivities of antibiotic combinations against resistant strains of Pseudomonas aeruginosa in a model of infected THP-1 monocytes.Interactions of oritavancin, a new lipoglycopeptide derived from vancomycin, with phospholipid bilayers: Effect on membrane permeability and nanoscale lipid membrane organization.Quantitative analysis of gentamicin, azithromycin, telithromycin, ciprofloxacin, moxifloxacin, and oritavancin (LY333328) activities against intracellular Staphylococcus aureus in mouse J774 macrophagesActive efflux of ciprofloxacin from J774 macrophages through an MRP-like transporter.Intracellular pharmacodynamics of antibiotics.Role of acidic pH in the susceptibility of intraphagocytic methicillin-resistant Staphylococcus aureus strains to meropenem and cloxacillinRX-P873, a Novel Protein Synthesis Inhibitor, Accumulates in Human THP-1 Monocytes and Is Active against Intracellular Infections by Gram-Positive (Staphylococcus aureus) and Gram-Negative (Pseudomonas aeruginosa) Bacteria.Modulation of the cellular accumulation and intracellular activity of daptomycin towards phagocytized Staphylococcus aureus by the P-glycoprotein (MDR1) efflux transporter in human THP-1 macrophages and madin-darby canine kidney cells.Cellular pharmacodynamics and pharmacokinetics of antibiotics: current views and perspectives.Adverse drug reactions to antiretroviral therapy: prospective study in children in sikasso (mali).Cellular pharmacokinetics of telavancin, a novel lipoglycopeptide antibiotic, and analysis of lysosomal changes in cultured eukaryotic cells (J774 mouse macrophages and rat embryonic fibroblasts).Cellular pharmacokinetics and pharmacodynamics of the glycopeptide antibiotic oritavancin (LY333328) in a model of J774 mouse macrophages.Pharmacodynamic evaluation of the intracellular activity of antibiotics towards Pseudomonas aeruginosa PAO1 in a model of THP-1 human monocytes.Restoration of susceptibility of intracellular methicillin-resistant Staphylococcus aureus to beta-lactams: comparison of strains, cells, and antibiotics.Multidrug-resistant Streptococcus pneumoniae infections: current and future therapeutic options.A combined pharmacodynamic quantitative and qualitative model reveals the potent activity of daptomycin and delafloxacin against Staphylococcus aureus biofilms.Tissue concentrations: do we ever learn?Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: pharmacodynamic evaluation and comparison with isogenic normal-phenoThe antifungal caspofungin increases fluoroquinolone activity against Staphylococcus aureus biofilms by inhibiting N-acetylglucosamine transferase.
P50
Q28243911-34BC85E6-D1DF-46ED-AA91-247C643D6939Q28478263-23A3CBA4-3432-4FEB-884D-246917395807Q28487758-FBB8D452-4D8A-43FC-B977-A6203F19B853Q30597709-4EB64013-B66B-4328-9A9E-29E73CD80A36Q31031926-7A44EEA0-BF8A-40C1-9B9F-B9538FAF54FEQ33214516-128C01BD-AA04-472D-9777-929AB8974CBAQ33401731-BC1E490E-F66D-4E6C-BF2E-0D41004B947DQ33510966-7DF1A1DB-6CF2-4F33-A8C6-99BD2B2AC328Q33571444-426DA61F-1AE5-4A26-BA18-4C0B8021A7C6Q33721961-17E4BB07-70FD-4E26-B592-4912D0504E5FQ33770082-ABEC9CEA-38F9-43CC-9DAA-3298F9944EC6Q33876454-EB78CFEA-EC05-4EF3-9B69-CA33811C20F5Q34089765-972BF646-B6B7-463B-85BD-300AE1BD29DDQ34109849-F6624170-CDB9-4D86-ABCF-3D5EAEE1777BQ34111057-439FA61C-1D00-433B-92CA-1E096BE28DC2Q34310568-A79352C2-425C-4FC7-AA9D-2A1CF1C68CEAQ34390844-4C977161-1CCB-4359-9089-3D5936E691A6Q34618656-2EA91E5D-2B2E-4B9F-943D-9D32CB1E7339Q34648829-5228F440-209F-4AD0-BAF1-EAD257099BE8Q34734399-50A5C401-440B-456C-BF1F-B04A0A92130EQ34922189-4160B3CF-A225-4322-9193-1184C5528869Q34922363-59290CEA-715C-4B11-A86E-604B0CEA0AA4Q34981587-86644522-F5AB-487D-B0D3-93B76A160EC3Q35102754-C7524F1B-F38A-4EB9-B8B2-06745CD63B04Q35125010-668F1682-C1ED-4787-9BB2-9F75B06F7ED3Q35623085-D7B44BF4-09F2-4C34-B109-85E3D2F8E039Q35759082-F185201D-A36B-4CAF-9401-B7C6B722120CQ35860120-147971AB-0885-4B33-B624-26A08EEDA07CQ35912731-59CF92E8-0CE6-4DE9-A110-D4C82572662EQ36432600-58A8F94C-AD38-40F9-9F0D-163A0E9AD6D2Q36596948-18E63A4D-36DB-4830-8C85-F05C7D5F130CQ36660619-EF39644F-FFF5-422E-8499-94E0617E767CQ36670964-1FB56EC4-8C90-4166-B54A-F6AB6BD74BA9Q36785824-C906BDCC-B08E-4ACF-B6D9-3CA2872B2AC5Q36804044-AEE125EF-167A-479D-87EF-3AAAAA7DB6EFQ36993388-41E31BB1-C03D-4E87-96C0-2C4096946FE5Q37026608-77427EB3-4287-4CA6-9B7F-3C9E3DF050E6Q37027052-008FE330-94B4-4180-B150-51FB007CB905Q37144809-7AA44F32-BFC4-4E70-A273-D043BA2407B8Q37396221-1CC20578-63D1-452F-9177-C7B724B1D4CA
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Paul M Tulkens
@ast
Paul M Tulkens
@en
Paul M Tulkens
@es
Paul M Tulkens
@nl
Paul M Tulkens
@sl
type
label
Paul M Tulkens
@ast
Paul M Tulkens
@en
Paul M Tulkens
@es
Paul M Tulkens
@nl
Paul M Tulkens
@sl
prefLabel
Paul M Tulkens
@ast
Paul M Tulkens
@en
Paul M Tulkens
@es
Paul M Tulkens
@nl
Paul M Tulkens
@sl
P1053
B-2087-2015
P106
P21
P31
P3829
P496
0000-0002-7121-3623